Dermata (DRMA) 10% Owner Gerald Proehl Receives Awards

What Happened Gerald T. Proehl, identified as a 10% owner of Dermata Therapeutics (DRMA), reported acquisitions on the Form 4. The filing shows he acquired 170,068 shares of common stock (or pre‑funded warrants in lieu thereof) and multiple related derivative warrants (several entries of 1,360,544 and 170,068 reported as derivative instruments). The purchase price disclosed in footnotes was $1.47 per share and $1.469 per pre‑funded warrant — the common‑share portion (170,068 × $1.47) is roughly $250,000. The securities were purchased in a private placement exempt under Rule 16b‑3(d)(1).

Key Details

• Transaction date(s): reported on the Form 4 with an effective/reporting period of 2025‑08‑16; the filing was made on 2026‑08‑18 (appears late).
• Reported items: 170,068 common shares (or pre‑funded warrants) plus multiple derivative warrant line items (1,360,544 and additional 170,068 counts as reported).
• Price: $1.47 per share; $1.469 per pre‑funded warrant (per footnote).
• Post‑transaction holdings: not specified in the provided filing excerpt.
• Notable footnotes: securities were bought in a private placement together with Series E and Series F warrants (F1); Series E warrants become exercisable upon stockholder approval and expire five years after approval (F3); Series F warrants become exercisable upon approval and expire two years after approval (F4); exercise is subject to a ~9.99% beneficial‑ownership cap; pre‑funded warrants have no expiration (F6); Reporting Person disclaims beneficial ownership except to the extent of pecuniary interest (F5).
• Timeliness: filing appears late (filed ~1 year after the report period), which can limit timely market transparency.

Context These entries represent a private‑placement purchase that included common (or pre‑funded) shares plus attached warrants. The warrants are derivative instruments that generally cannot be exercised until stockholder approval of the issuable shares and are subject to exercise/ownership limits. Because Proehl is a 10% owner (not necessarily an executive), these transactions are institutional/strategic purchases rather than routine officer trades; the late filing reduces the immediacy of this disclosure.